Information Provided By:
Fly News Breaks for September 7, 2016
SGEN
Sep 7, 2016 | 08:15 EDT
Morgan Stanley analyst Andrew Berens initiated Seattle Genetics with an Overweight and $60 price target. The analyst expects Adcetris will peak at $2.5B by 2030 and thinks the company is likely to move Adcetris to the frontline in Hodgkin's lymphoma treatment.
News For SGEN From the Last 2 Days
There are no results for your query SGEN